Genocea Biosciences, Inc.

Home » Genocea Biosciences, Inc.

Secondary

Genocea Biosciences, Inc.

Biopharmaceutical

We are a biopharmaceutical company that discovers and develops novel cancer immunotherapies using the ATLAS™ proprietary discovery platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or “antigen” in that patient's tumor.

Symbol

GNCA

Last Closing Price
$5.12

Shares
10,000,000

Anticipated Date
June 20, 2019

Underwriters
LEERINK SWANN & COMPANY

To view the prospectus for Genocea Biosciences, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253